DIABETES DEVICES AND DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Diabetes devices and drugs refer to the tools and medications specifically designed to help individuals manage and treat diabetes, a chronic metabolic disorder characterized by high blood sugar levels. These devices and drugs play a crucial role in monitoring blood glucose levels, delivering insulin, and controlling the symptoms and complications associated with diabetes. Glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, etc. are a few examples of devices that aid the management of diabetes. Whereas, drugs include insulin, metformin, sulfonylureas, amylin analogues, etc. These devices and drugs are essential for individuals with diabetes to monitor their blood sugar levels, administer insulin, and manage the condition effectively, thereby reducing the risk of complications and promoting overall well-being.

Market Dynamics

The global prevalence of diabetes has been rising steadily primarily driven by the factors such as sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates. This surge in the diabetic population has created a substantial demand for effective devices and drugs to monitor and treat the condition. In terms of devices, continuous glucose monitoring systems have gained significant popularity. For instance, in March 2022, DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System received CE Mark (Conformité Européenne) for people with diabetes in Europe aged 2 and above, including pregnant women.

The market for diabetes drugs has also witnessed remarkable advancements. Traditional treatments, such as oral antidiabetic drugs and insulin injections, continue to dominate the market. However, there has been a growing emphasis on the development of novel drugs, including incretin-based therapies, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, and (Glucagon-like Peptide-1) GLP-1 receptor agonists. These innovative medications offer improved efficacy and reduced side effects, and enhanced convenience for patients.

Key features of the study

• This report provides an in-depth analysis of the global diabetes devices and drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global diabetes devices and drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global diabetes devices and drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetes devices and drugs market

Market Segmentation

• Global Diabetes Devices and Drugs Market, By Category
  • Diagnosis and Monitoring
    • Blood Glucose Monitoring Devices
    • Software Programs for Diabetes Monitoring
    • Artificial Pancreas
    • Other Testing Devices
  • Therapeutics
    • Insulin
    • Insulin Delivery
    • Oral Hypoglycemic Agents
    • Cell Therapies
• Global Diabetes Devices and Drugs Market, By Disease Type
  • Type 2 Diabetes
  • Type 1 Diabetes
• Global Diabetes Devices and Drugs Market, By Region
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • DexCom
  • Eli Lilly and Company
  • Companion Medical
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Johnson & Johnson
  • Lupin Ltd.
  • Hoffmann-La Roche AG
  • DreaMed Diabetes
  • Hua Medicine
  • Sanofi